E-mail this page Printer Friendly Version RSS E-mail Alerts View contacts Download Financial Tear Sheet 

2015 Press Releases

This section of the website contains information that should be considered accurate as of the date presented. You acknowledge that this information may change over time and you should not assume that the information is accurate at a later date. Quest Diagnostics is not obligated to update the information contained in this section of the website.

Keyword Search
 
2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007
DateTitle 
12/23/15New York Giants Incorporate Sports Science from Quest Diagnostics into Training
Quest Diagnostics Blueprint for Athletes™ provides new laboratory diagnostics for professional and amateur athletes EAST RUTHERFORD, N.J., Dec. 23, 2015 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX) and the New York Football Giants today made it official: Giants' players are now using Quest's baseline athletic performance testing service "Blueprint for Athletes," which has been a major factor for the Giants' training and preparation for NFL games this season.  The Blueprint for Athlet... 
Printer Friendly Version
12/10/15Quest Diagnostics, Barnabas Health Enter Into Strategic Laboratory Partnership To Deliver High-value And Innovative Diagnostic Information Services
MADISON, N.J. and WEST ORANGE, N.J., Dec. 10, 2015 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, and Barnabas Health, New Jersey's largest not-for-profit integrated health care delivery system, are teaming up to enhance quality and value of diagnostic services to patients and their doctors through an agreement for Quest to manage laboratory operations for Barnabas Health hospitals. Under the agreement, Quest Diagnostics will... 
Printer Friendly Version
12/04/15Quest Diagnostics Declares Quarterly Cash Dividend
MADISON, N.J., Dec. 4, 2015 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, today announced that its Board of Directors declared a quarterly cash dividend of $0.38 per share, payable on Jan. 27, 2016 to shareholders of record of Quest Diagnostics common stock on Jan. 12, 2016. About Quest Diagnostics Quest Diagnostics empowers people to take action to improve health outcomes.  Derived from the world's largest data... 
Printer Friendly Version
12/04/15Quest Diagnostics Increases Share Repurchase Authority by $500 Million
MADISON, N.J., Dec. 4, 2015 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, today announced that its Board of Directors has increased the company's share repurchase authorization by $500 million. The $500 million authorization announced today is an increase to the $522 million that was available as of Sept. 30, 2015 under the company's share repurchase authorization program.  Fourth quarter repurchases will be repor... 
Printer Friendly Version
12/03/15Quest Diagnostics Streamlines Hepatitis C Virus Lab Testing by Performing Molecular Testing for all Positive Antibody Test Results
MADISON, N.J., December 3, 2015 – In its commitment to provide diagnostic insights that enhance patient care and outcomes, Quest Diagnostics (NYSE: DGX) will automatically perform molecular testing on all patient specimens whose antibody screening results indicate hepatitis C virus infection, and remove standalone positive antibody screening as a test option. The change to the company’s service menu eliminates the prospect a patient may receive a positive screening result but fail to unde... 
Printer Friendly Version
11/10/15Quest Diagnostics to Acquire Clinical Laboratory Partners' Outreach Laboratory Service Business in Connecticut
Acquisition to Enhance Access to Innovative, High-value Diagnostic Information Services for People in Connecticut MADISON, N.J. and HARTFORD, Conn., Nov. 10, 2015 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced it has entered into a definitive agreement to acquire the outreach laboratory service business of Clinical Laboratory Partners (CLP), a wholly-owned subsidiary of Hartford HealthCare (HHC). HHC is an inte... 
Printer Friendly Version
10/22/15Quest Diagnostics Reports Third Quarter 2015 Financial Results
- Revenues of $1.88 billion, up 0.9% on an equivalent basis vs. 2014; down 1.3% on a reported basis vs. 2014 - Adjusted diluted EPS excluding amortization of $1.28, up 6.7% vs. 2014 - Reported diluted EPS of $2.35, up 167% vs. 2014 including gain on contribution to clinical trials joint venture - Full year adjusted diluted EPS outlook narrowed to $4.75 - $4.80 MADISON, N.J., Oct. 22, 2015 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of di... 
Printer Friendly Version
10/21/15Quest Diagnostics' ExamOne Life Insurance Testing Business to Acquire Superior Mobile Medics
Transaction to Expand Paramedical Services Offering for Insurers, Brokerages and Life Insurance Applicants MADISON, N.J., Oct. 21, 2015 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, announced today that its ExamOne business, the leader in helping insurers meet their underwriting needs, has agreed to acquire the business assets of Superior Mobile Medics. Based in San Diego, Calif., Superior Mobile Medics is a national pro... 
Printer Friendly Version
10/09/15Quest Diagnostics Introduces Dako's PD-L1 Complementary Diagnostic Test to Support Bristol-Myers Squibb's OPDIVO® Anti-PD-1 Therapy for Non-squamous Non-small Cell Lung Cancer
The new Quest test service is based on the first FDA-approved complementary diagnostic MADISON, N.J., Oct. 9, 2015 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced that it now provides clinical laboratory testing using the  PD-L1 IHC 28-8 pharmDx immunohistochemistry test, available through Dako, an Agilent Technologies company.  Today, the U.S. Food and Drug Administration (FDA) approved Bristol-Myers Squi... 
Printer Friendly Version
10/08/15Testing for More Cystic Fibrosis Mutations than Recommended by Current Medical Guidelines May Identify A Greater Number of Potential Carriers, Finds Study Presented at 2015 ASHG Annual Meeting
Scientists from Quest Diagnostics also provide an oral presentation on the novel "molecular combing" technique's ability to identify gene mutations to aid diagnosis of a form of muscular dystrophy MADISON, N.J., Oct. 8, 2015 /PRNewswire/ -- Genetic testing for mutations beyond those currently recommended in medical guidelines may aid the identification of more couples at risk of having a child with cystic fibrosis, according to a study presented today at the 2015 American Society of Human G... 
Printer Friendly Version
10/06/15FDA Clears the Focus Diagnostics Simplexa™ Flu A/B & RSV Direct Test to Include 53 New Virus Strains for the 2015-2016 Flu Season
Molecular test from Quest Diagnostics' products business is cleared to identify 92 influenza and respiratory syncytial virus strains, more than any other FDA-cleared molecular test CYPRESS, Calif. and MADISON, N.J., Oct. 6, 2015 /PRNewswire/ -- In advance of the 2015-2016 flu season, Focus Diagnostics, the products business of Quest Diagnostics (NYSE: DGX), today announced that its Simplexa™ Flu A/B & RSV Direct Kit has received 510(k) clearance from the U.S. Food and Drug Administratio... 
Printer Friendly Version
10/05/15Quest Diagnostics To Release Third Quarter 2015 Financial Results On October 22
MADISON, N.J., Oct. 5, 2015 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced that it will report third quarter 2015 results on Thursday, October 22, 2015, before the market opens. It will hold its quarterly conference call to discuss the results beginning at 8:30 a.m. Eastern Time on that day. The conference call can be accessed in listen-only mode by dialing 415-228-4961, passcode 3214469. The company sug... 
Printer Friendly Version
10/02/15Quest Diagnostics Introduces Dako's PD-L1 Companion Diagnostic for KEYTRUDA®, Merck's Anti-PD-1 Therapy for Metastatic Non-Small Cell Lung Cancer Whose Tumors Express PD-L1 with Disease Progression On or After Platinum-Containing Chemotherapy
Testing by Quest will advance precision medicine by helping to identify patients who may benefit from new oncology immunotherapy MADISON, N.J., Oct. 2, 2015 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced that it will provide clinical laboratory testing using the PD-L1 IHC 22C3 PharmDx™ immunohistochemistry companion diagnostic. Earlier today, the U.S. Food and Drug Administration (FDA) approved Merck's KEY... 
Printer Friendly Version
09/29/15Quest Diagnostics and Inovalon Advance Value-Based Healthcare with Industry-First Real-Time Analytics at the Point of Care
"Data Diagnostics™" provides valuable on-demand insights to align clinical management with quality, utilization and financial performance goals MADISON, N.J., Sept. 29, 2015 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, and Inovalon (Nasdaq: INOV), a leading technology company providing advanced, cloud-based data analytics and data-driven intervention platforms to the healthcare industry, today announced the national launch o... 
Printer Friendly Version
09/14/15Quest Diagnostics Sustainability Efforts Earn Continued Place on 2015 DJSI World and National Indices
MADISON, N.J., Sept. 14, 2015 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, was named for the eleventh consecutive year in the North America Dow Jones Sustainability Index (DJSI) and for a twelfth year in the World DJSI. The Dow Jones Sustainability Index provides an integrated assessment of companies based on economic, environmental and social criteria with a strong focus on long-term shareholder value. To be included or rem... 
Printer Friendly Version
09/11/15Quest Diagnostics To Speak At The Morgan Stanley Global Healthcare Conference
MADISON, N.J., Sept. 11, 2015 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced that it is scheduled to speak at the Morgan Stanley Global Healthcare Conference in New York City. Steve Rusckowski, the company's President and CEO, will discuss the company's vision, goals and five point strategy. The presentation is scheduled for Thursday, September 17, 2015 at 11:10 a.m. Eastern Time. The presentation will b... 
Printer Friendly Version
09/10/15Quest Diagnostics To Speak At The 10th Annual Wells Fargo Healthcare Conference
MADISON, N.J., Sept. 10, 2015 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced that it is scheduled to speak at the 10th Annual Wells Fargo Healthcare Conference in New York City.  Mark Guinan, the company's Senior Vice President and CFO, will discuss the company's vision, goals and five point strategy. The presentation is scheduled for today, Thursday, September 10, 2015 at 9:10 a.m. Eastern Time. The pre... 
Printer Friendly Version
09/10/15One in Two Adolescents Misuse Their Prescription Drugs, Study Shows
Analysis by Quest Diagnostics of 2.5 million de-identified test results finds about half of patients of all ages are still taking opioids and other potentially addictive medications inappropriately MADISON, N.J., Sept. 10, 2015 /PRNewswire/ -- Although prescription drug misuse is on the decline among adolescents, one in two patients tested between the ages of 10 and 17 years are not using their medications appropriately, potentially putting their health at risk, according to an analysis by ... 
Printer Friendly Version
09/03/15Focus Diagnostics Receives FDA Clearance to Add Genital Swab Claim to Moderate Complexity Simplexa™ HSV 1 & 2 Direct Molecular Test
System from Quest Diagnostics' products business is first FDA-cleared Herpes Simplex Virus 1 and 2 test that uses genital swab or cerebrospinal fluid (CSF) specimen collection MADISON, N.J. and CYPRESS, Calif., Sept. 3, 2015 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced that its Focus Diagnostics products business has received FDA 510(k) clearance to add the genital swab claim to its Simplexa HSV 1 & 2 Dir... 
Printer Friendly Version
08/18/15Quest Diagnostics Declares Quarterly Cash Dividend
MADISON, N.J., Aug. 18, 2015 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced that its Board of Directors declared a quarterly cash dividend of $0.38 per share, payable on October 21, 2015 to shareholders of record of Quest Diagnostics common stock on October 6, 2015. About Quest Diagnostics Quest Diagnostics empowers people to take action to improve health outcomes.  Derived from the world's largest database of... 
Printer Friendly Version
08/04/15Quest Diagnostics Completes Acquisition of MemorialCare Health System's Laboratory Outreach Service Business in Southern California
MADISON, N.J. and LOS ANGELES, Aug. 4, 2015 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced that it has completed the previously announced acquisition of MemorialCare Health System's laboratory outreach service business. As a result of the transaction, patients and physicians now have access to Quest's extensive range of innovative services and network of nearly 200 patient service centers in southern Californi... 
Printer Friendly Version
07/29/15Quest Diagnostics Collaborates with Perinatal Quality Foundation on National Initiative to Advance Clinically Appropriate Noninvasive Prenatal Screening
Educational campaign and patient registry to provide new insights and clarification on use of advanced screening tests to assess fetal health while promoting outcomes research on tests' predictive accuracy WASHINGTON, July 29, 2015 /PRNewswire/ -- The Perinatal Quality Foundation (PQF) today announced a nationwide campaign to improve understanding of the advantages, limitations and clinically appropriate interpretation of results of noninvasive prenatal screening and other diagnostic tests ... 
Printer Friendly Version
07/23/15Quest Diagnostics Reports Second Quarter 2015 Financial Results
- Revenues of $1.93 billion, up 1.2% from 2014 - Adjusted diluted EPS excluding amortization of $1.25, up 5.0% from 2014 - Reported diluted EPS of $0.81 was negatively impacted by debt refinancing and other charges - Revenue outlook updated to reflect recently completed joint venture with Quintiles - Full year 2015 outlook for adjusted diluted EPS excluding amortization of $4.70 to $4.85, unchanged MADISON, N.J., July 23, 2015 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE... 
Printer Friendly Version
07/07/15Quest Diagnostics To Release Second Quarter 2015 Financial Results On July 23
MADISON, N.J., July 7, 2015 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced that it will report second quarter 2015 results on Thursday, July 23, 2015, before the market opens. It will hold its quarterly conference call to discuss the results beginning at 8:30 a.m. Eastern Time on that day. The conference call can also be accessed in listen-only mode by dialing 415-228-4961, passcode 3214469. The company ... 
Printer Friendly Version
07/02/15Quintiles and Quest Diagnostics Launch Q2 Solutions
Closes previously announced clinical trials laboratory services joint venture transaction RESEARCH TRIANGLE PARK, N.C. & MADISON, N.J.--(BUSINESS WIRE)-- Quintiles and Quest Diagnostics today announced the launch of Q2 Solutions, their new combined clinical trials laboratory services organization. Q2 Solutions brings together the clinical trials laboratory operations of the two parent organizations to provide biopharmaceutical customers with the diverse capabilitie... 
Printer Friendly Version
06/30/15Quest Diagnostics to Acquire MemorialCare Health System's Laboratory Outreach Service Business
Transaction to Extend Laboratory Partnership Serving Patients and Physicians in Southern California while Bolstering Quest's Growth Strategy in the Region MADISON, N.J. and LOS ANGELES, June 30, 2015 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, and MemorialCare Health System, a nationally recognized nonprofit health system in Los Angeles and Orange counties, today announced they have entered into a definitive agreement for Q... 
Printer Friendly Version
06/16/15Physicians Rank Quest Diagnostics Care360 Top EHR for Small Group Practices in 2015 Black Book Survey
MADISON, N.J., June 16, 2015 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced that its Care360 cloud-based electronic health record (EHR) has ranked number one among physician practices and groups with two to five practicing physicians. The ranking is based on a poll of 5,700 small and solo medical practices surveyed by Black Book™ in 2015. Physicians across all specialties in these small-sized practices ranked C... 
Printer Friendly Version
06/09/15Quest Diagnostics to Comment on 2015 Revenue Outlook in Light of Joint Venture Progress at Goldman Sachs 36th Annual Global Healthcare Conference
MADISON, N.J., June 9, 2015 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced that, in light of recent progress in finalizing its clinical trials joint venture, Mark Guinan, the company's Senior Vice President and CFO, will provide commentary on its revenue outlook when he presents at the Goldman Sachs 2015 Global Healthcare Conference in Rancho Palos Verdes, California on June 10. On March 31, 2015, Quest... 
Printer Friendly Version
06/09/15Illicit Drug Positivity Rate Increases Sharply in Workplace Testing, Finds Quest Diagnostics Drug Testing Index™ Analysis
Upsurge in marijuana, cocaine and methamphetamine drive second consecutive year of increases in the positivity rate for drug tests, suggesting a potential reversal in a decades' long decline in workforce drug use MADISON, N.J., June 9, 2015 /PRNewswire/ -- The percentage of American workers testing positive for illicit drugs such as marijuana, cocaine and methamphetamine has increased for the second consecutive year in the general U.S. workforce, according to insights from more than 10 mill... 
Printer Friendly Version
06/05/15Quest Diagnostics to Speak at the Goldman Sachs 36th Annual Global Healthcare Conference
MADISON, N.J., June 5, 2015 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced that it is scheduled to speak at the Goldman Sachs 2015 Global Healthcare Conference in Rancho Palos Verdes, California. Mark Guinan, the company's Senior Vice President and CFO, will discuss the company's vision, goals and five point strategy.  The presentation is scheduled for Wednesday, June 10, 2015 at 2:20 p.m. Eastern Daylight Ti... 
Printer Friendly Version
05/28/15Quest Diagnostics to Speak at the Jefferies 2015 Global Healthcare Conference
MADISON, N.J., May 28, 2015 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced that it is scheduled to speak at the Jefferies 2015 Global Healthcare Conference in New York.  Steve Rusckowski, the company's President and CEO, will discuss the company's vision, goals and five point strategy.  The presentation is scheduled for Tuesday, June 2, 2015 at 8:00 a.m. Eastern Time. The presentation will be webcast liv... 
Printer Friendly Version
05/15/15Quest Diagnostics Declares Quarterly Cash Dividend
MADISON, N.J., May 15, 2015 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced that its Board of Directors declared a quarterly cash dividend of $0.38 per share, payable on July 22, 2015 to shareholders of record of Quest Diagnostics common stock on July 8, 2015. About Quest Diagnostics Quest Diagnostics empowers people to take action to improve health outcomes.  Derived from the world's largest database of clin... 
Printer Friendly Version
05/12/15Quest Diagnostics to Enhance Quality of Noninvasive Prenatal Screening with QNatal Advanced™
New prenatal screening service provides actionable information for women with high-risk pregnancies MADISON, N.J., May 12, 2015 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services and a leader in women's health and genomic testing, today launched QNatal Advanced, a noninvasive prenatal screening service for detecting chromosomal abnormalities in high-risk pregnancies. QNatal Advanced analyzes ... 
Printer Friendly Version
05/04/15Quest Diagnostics Announces LeukoVantage™, Advancing Precision Medicine for Hematologic Malignancies
Genomic service detects 30 gene mutations to aid in the diagnosis, prognosis, monitoring and treatment selection for several myeloid neoplasms MADISON, N.J., May 4, 2015 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced LeukoVantage™, an evidence-based genomic test service that aids in the diagnosis, prognosis, monitoring and selection of treatment for myeloid neoplasms, a group of hematologic malignancies that in... 
Printer Friendly Version
04/23/15Quest Diagnostics Reports First Quarter 2015 Financial Results
-- Revenues of $1.84 billion, up 5.3% from 2014 -- Adjusted diluted EPS excluding amortization of $1.05, up 13% from 2014 -- Reported diluted EPS of $0.42 was negatively impacted by recent debt refinancing charges -- Guidance unchanged for full year revenue and adjusted diluted EPS excluding amortization MADISON, N.J., April 23, 2015 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced today that for ... 
Printer Friendly Version
04/21/15Quest Diagnostics and Inserm Launch Multinational BRCA Gene Datashare Initiative, with LabCorp as First Participant, to Improve the Detection of Inherited Risk of Breast and Ovarian Cancers
BRCA Share™ is a novel public-private initiative designed to enhance the clarity and quality of patient testing MADISON, N.J. and PARIS and BURLINGTON, N.C., April 21, 2015 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, and Inserm, the French National Institute of Health and Medical Research institution, today launched BRCA Share™, a novel datashare initiative they co-founded to provide scientists and laboratory organizations ... 
Printer Friendly Version
04/15/15FDA Clears the Simplexa™ Group A Strep Direct Test from Focus Diagnostics, a Quest Diagnostics Business
CYPRESS, Calif. and MADISON, N.J., April 15, 2015 /PRNewswire/ -- Focus Diagnostics, the clinical-laboratory products business of Quest Diagnostics (NYSE: DGX), today announced the FDA 510(k) clearance and CLIA moderate-complexity categorization for its Simplexa Group A Strep Direct Kit.  Simplexa Group A Strep Direct is a real-time polymerase chain reaction assay for the detection of Group A Streptococcus bacteria directly from throat swabs.  The most prevalent form of Group A Streptococcus... 
Printer Friendly Version
04/14/15HPV-Only Screening Misses More Cervical Cancers in Women 30 and Older Than Pap-Only or Pap-HPV Co-testing, Finds National Study
As many as 19% of women received false negatives for cervical cancer when HPV-only tested, finds Quest Diagnostics Health Trends™ study published in Cancer Cytopathology of 256,648 women, one of the largest of different screening tests for cervical cancer MADISON, N.J., April 14, 2015 /PRNewswire/ -- HPV-only screening is less likely to accurately detect cervical pre-cancer and cancer than testing that includes a Pap test in women 30-65 years of age, according to a new study published onlin... 
Printer Friendly Version
04/13/15Quest Diagnostics To Release First Quarter 2015 Financial Results On April 23
MADISON, N.J., April 13, 2015 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced that it will report first quarter 2015 results on Thursday, April 23, 2015, before the market opens. It will hold its quarterly conference call to discuss the results beginning at 8:30 a.m. Eastern Time on that day. The conference call can also be accessed in listen-only mode by dialing 415-228-4961, passcode 3214469. The compan... 
Printer Friendly Version
04/09/15Quest Diagnostics to Launch Interactive Insights and IntelliTest Interactive Reports and Health Data Analytics Tools at HIMSS 2015
Company's HIT solutions turn health information into actionable insights to help ACOs, health systems, hospitals and physicians improve health care quality, outcomes and efficiencies MADISON, N.J., April 9, 2015 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, will unveil a suite of new technology solutions during the HIMSS 2015 Annual Conference & Exhibition, the industry's largest health IT educational program and exhibiti... 
Printer Friendly Version
04/02/15Quest Diagnostics Recognizes Five Strategic Partners with Supplier Excellence Awards
MADISON, N.J., April 2, 2015 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today awarded Supplier Excellence Awards to five companies at its 2015 Supplier Forum. Supplier Excellence awards recognize world class products, systems, or services that provide consistent and reliable performance; companies that develop and implement novel solutions to move the business forward; individuals who step up to the challenge and excel in ... 
Printer Friendly Version
03/31/15Quintiles and Quest Diagnostics to Form Joint Venture to Provide Global Clinical Trials Laboratory Services
Combines the complementary strengths and scale of leading biopharmaceutical services and diagnostic information services providers New entity creates superior value proposition through the depth and scale of its capabilities, services and expertise Business to help biopharmaceutical customers bring new drug therapies to market and support precision medicine Joint venture would have generated approximately $575 million in revenues in 2014 Quintiles will own 60% and Quest D... 
Printer Friendly Version
03/23/15Diabetes Diagnoses Surge in States that Expanded Medicaid Under the Affordable Care Act
Quest Diagnostics Health Trends™ study in Diabetes Care suggests health care reform has increased access to preventive health services, but only in states that expanded Medicaid MADISON, N.J., March 23, 2015 /PRNewswire/ -- People in states that expanded Medicaid under the Affordable Care Act (ACA) are far more likely to be newly identified with diabetes than in states that elected not to expand the public health care program, finds a new study by researchers at Quest Diagnostics (NYSE: DGX... 
Printer Friendly Version
03/19/15Quest Diagnostics Announces Early Tender Date Results of Cash Tender Offers for Up to $250 Million Combined Aggregate Principal Amount of Certain of its Outstanding Notes
MADISON, N.J., March 19, 2015 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced today the early tender results of its previously announced cash tender offers (each, an "Offer" and, collectively, the "Offers") to purchase up to $250 million combined aggregate principal amount (the "Maximum Tender Amount") of its 6.950% Senior Notes due 2037 (the "2037 Notes") and 5.750% Senior Notes due 2040 (the "2040 Notes" and... 
Printer Friendly Version
03/18/15Quest Diagnostics Announces Pricing of Cash Tender Offers for Up to $250 Million Combined Aggregate Principal Amount of Certain of its Outstanding Notes
MADISON, N.J., March 18, 2015 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced today the determination of the pricing for its previously announced cash tender offers (each, an "Offer" and, collectively, the "Offers") to purchase up to $250 million combined aggregate principal amount (the "Maximum Tender Amount") of its 6.950% Senior Notes due 2037 (the "2037 Notes") and 5.750% Senior Notes due 2040 (the "2040 N... 
Printer Friendly Version
03/10/15Quest Diagnostics to Enhance Diagnosis of Pediatric Neurological Disorders with Exclusive Whole Exome Sequencing from Personalis
Proprietary Neurome™ service provides insight into the genetic causes of neurological disorders so parents and health care providers can develop personalized care strategies MADISON, N.J., March 10, 2015 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced the availability of Neurome™, a whole exome sequencing service designed to aid the diagnosis of rare neurological disorders in pediatric populations. Personalis, I... 
Printer Friendly Version
03/05/15Quest Diagnostics Incorporated Announces Proposed Senior Notes Offering
MADISON, N.J., March 5, 2015 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced today that it intends to offer $1,200,000,000 in aggregate principal amount of three series of senior notes in a public offering made under a shelf registration statement filed with the Securities and Exchange Commission, subject to market and other conditions. The issuance of the notes will be subject to customary closing condi... 
Printer Friendly Version
03/05/15Quest Diagnostics Commences Cash Tender Offer for Up to $250 Million Combined Aggregate Principal Amount of Certain of its Outstanding Notes
MADISON, N.J., March 5, 2015 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced today that it has commenced cash tender offers (each, an "Offer" and, collectively, the "Offers") to purchase up to $250 million combined aggregate principal amount (the "Maximum Tender Amount") of its 6.950% Senior Notes due 2037 and 5.750% Senior Notes due 2040 (collectively, the "Notes"). The terms and conditions of the Offers are ... 
Printer Friendly Version
03/05/15Quest Diagnostics Announces Amendments to the Prices Offered in its Previously Announced Cash Tender Offer for Up to $250 Million Combined Aggregate Principal Amount of Certain of its Outstanding Notes
MADISON, N.J., March 5, 2015 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced today that it is amending the terms of its cash tender offers (each, an "Offer" and, collectively, the "Offers") to purchase up to $250 million combined aggregate principal amount (the "Maximum Tender Amount") of its 6.950% Senior Notes due 2037 (the "2037 Notes") and 5.750% Senior Notes due 2040 (the "2040 Notes" and, together with t... 
Printer Friendly Version
03/04/15Quest Diagnostics To Speak At The Barclays Global Healthcare Conference
MADISON, N.J., March 4, 2015 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced that it is scheduled to speak at the Barclays Global Healthcare Conference in Miami.  Mark Guinan, the company's Senior Vice President and CFO, will discuss the company's vision, goals and five point strategy. The presentation is scheduled for Wednesday, March 11, 2015 at 1:05 p.m. Eastern Time. The presentation will be webcast l... 
Printer Friendly Version
02/20/15Quest Diagnostics Earns Fortune Magazine 2015 "World's Most Admired Companies" Designation
MADISON, N.J., Feb. 20, 2015 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced that it has been named a "Most Admired Company" by Fortune Magazine in the "Health Care: Pharmacy and Other Services" category. "We are proud that Quest Diagnostics is included on FORTUNE's 2015 World's Most Admired Companies list in our category," said Steve Rusckowski, President and CEO. "The honor is a true team accomplishment, and ... 
Printer Friendly Version
02/09/15Quest Diagnostics and Myriad Genetics End BRCA Patent Litigation
Agreement ensures continuing broad patient access to Quest's BRCAvantage™ services for evaluating genetic risk of developing breast, ovarian and other cancers MADISON, N.J., Feb. 9, 2015 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced that it and Myriad Genetics Inc. have reached an agreement that ends their BRCA gene-patent litigation.  Under the agreement, Quest Diagnostics and Myriad Genetics and its co-... 
Printer Friendly Version
01/29/15Quest Diagnostics Reports Fourth Quarter and Full Year 2014 Financial Results; Provides Guidance For Full Year 2015; Increases Dividend 15%
MADISON, N.J., Jan. 29, 2015 /PRNewswire/ -- Fourth quarter revenues from continuing operations of $1.9 billion, up 7.2% versus prior year Adjusted diluted EPS from continuing operations of $1.08, up 4.9% versus prior year Reported diluted EPS from continuing operations of $1.26, up 30% versus prior year Dividend increased 15% to $0.38 per quarter Full year 2015 revenues to grow 2% to 3% Full year 2015 adjusted diluted EPS excluding amortization expense expected to be between $4.... 
Printer Friendly Version
01/28/15Quest Diagnostics and CDC Expand Public Health Collaboration to Improve Hepatitis Diagnosis and Treatment
Multi-year fee-based contract for Quest's test data and analytics expertise aims to reveal insights from national testing trends to promote guideline-based care and better outcomes for 4.4 million Americans with viral hepatitis MADISON, N.J. and ATLANTA, Jan. 28, 2015 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced that it will collaborate with the Centers for Disease Control and Prevention (CDC) to identify tre... 
Printer Friendly Version
01/13/15Quest Diagnostics To Release Fourth Quarter And Full Year 2014 Financial Results On January 29
MADISON, N.J., Jan. 13, 2015 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced that it will report fourth quarter and full year 2014 results on Thursday, January 29, 2015, before the market opens. It will hold its quarterly conference call to discuss the results beginning at 8:30 a.m. Eastern Time on that day. The conference call can also be accessed in listen-only mode by dialing 415-228-4961, passcode 321... 
Printer Friendly Version
01/08/15Quest Diagnostics Names New Health Plan Leader
MADISON, N.J., Jan. 8, 2015 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced the appointment of veteran health plan executive Michael Cole as vice president of health plans for Quest Diagnostics.  "We are very focused on strengthening our relationships with health plan customers," said Steve Rusckowski, president and chief executive officer, Quest Diagnostics.  "Mike has the experience and leadership to build an... 
Printer Friendly Version
01/06/15Quest Diagnostics To Speak At The 33rd Annual J.P. Morgan Healthcare Conference
MADISON, N.J., Jan. 6, 2015 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced that it is scheduled to speak at the 33rd Annual J.P. Morgan Healthcare Conference in San Francisco.  Steve Rusckowski, the company's President and CEO, will discuss the company's vision, goals and five point strategy. The presentation is scheduled for Wednesday, January 14, 2015 at 2:30 p.m. Eastern Time. The presentation will be... 
Printer Friendly Version
01/05/15Quest Diagnostics to Speak at the Goldman Sachs Healthcare CEOs Unscripted Conference
MADISON, N.J., Jan. 5, 2015 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced that it is scheduled to speak at the Goldman Sachs Healthcare CEOs Unscripted Conference in Boston.  Steve Rusckowski, the company's President and CEO, will discuss the company's vision, goals and five point strategy. The presentation is scheduled for Tuesday, January 6, 2015 at 11:00 a.m. Eastern Time. The presentation will be we... 
Printer Friendly Version